We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Cholesterol-Free Mice to Aid Drug Development

By Biotechdaily staff writers
Posted on 13 Jan 2004
Researchers have developed a line of genetically engineered mice that are unable to synthesize cholesterol and instead use a different sterol, called desmosterol. More...


Investigators at Quark Biotech, Inc. (Ness Ziona, Israel) bred mice lacking the gene Dhcr24, which encodes the enzyme desmosterol reductase, the catalyst for the last stage of cholesterol synthesis, a process involving 20 steps and at least 19 enzymes.

It was possible to develop these mice because during gestation mice get their cholesterol from their mother, unlike humans, where the fetus must rely on its own production of cholesterol. The cholesterol-free mice were smaller than normal mice and are also infertile but otherwise relatively healthy. The physical condition of the mice was much better than had been expected, considering the severe defects that had been observed in the two patients suffering from demosterolosis caused by an autosomal recessive condition.

"We were surprised by the fact that a mouse lacking cholesterol can survive and develop into adulthood with little effect, when cholesterol accounts for approximately 99% of all steroids in mammals,” said senior author Dr. Elena Feinstein, vice-president for technology development at Quark Biotech. "We believe that this mouse can become a highly resourceful tool to further understand the role of cholesterol in the different organs. This knowledge can in the future help discover novel drugs and understand the mechanism of action of existing drugs for metabolic diseases and cancer, among others.”



Related Links:
Quark Biotech, Inc.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hematology Consumables
Bioblood Devices
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.